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Abstract Nucleolar protein interacting with the FHA domain of pKi-67 (NIFK) is a Ki-67-
interacting protein. However, its precise function in cancer remains largely uninvestigated. Here we
show the clinical significance and metastatic mechanism of NIFK in lung cancer. NIFK expression is
clinically associated with poor prognosis and metastasis. Furthermore, NIFK enhances Ki-67-
dependent proliferation, and promotes migration, invasion in vitro and metastasis in vivo via
downregulation of casein kinase 1a (CK1a), a suppressor of pro-metastatic TCF4/b-catenin
signaling. Inversely, CK1a is upregulated upon NIFK knockdown. The silencing of CK1a expression
in NIFK-silenced cells restores TCF4/b-catenin transcriptional activity, cell migration, and
metastasis. Furthermore, RUNX1 is identified as a transcription factor of CSNK1A1 (CK1a) that is
negatively regulated by NIFK. Our results demonstrate the prognostic value of NIFK, and suggest
that NIFK is required for lung cancer progression via the RUNX1-dependent CK1a repression,
which activates TCF4/b-catenin signaling in metastasis and the Ki-67-dependent regulation in cell
proliferation.
DOI: 10.7554/eLife.11288.001
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Introduction
The Ki-67 protein plays a specific but enigmatic role in cancer. Since its discovery as an antigen for a
monoclonal antibody against a Hodgkin lymphoma cell line more than 30 years ago (Gerdes et al.,
1983; Gerdes et al., 1984), Ki-67 serves as the most useful biomarker of cancer in clinical practice
(Brown and Gatter, 2002; Yerushalmi et al., 2010; Martin et al., 2004). The finding that Ki-67 is
exclusively expressed in the nucleus during all active cell cycle phases (G1, S, G2, and mitosis) in
actively proliferating cells but not in quiescent cells renders it a reliable marker for proliferation frac-
tion assessment (Gerdes et al., 1984). In many cancer types including breast (Luporsi et al., 2012),
lung (Jakobsen and Sorensen, 2013), brain (Abry et al., 2010), and prostate cancer (Fisher et al.,
2013), the Ki-67 expression level represents a proliferation index, and Ki-67 overexpression predicts
poor prognosis. Moreover, Ki-67 has also been used to determine cancer treatment strategies
(Dowsett et al., 2011). Ki-67 silencing was recently reported to elicit the disappearance of perichro-
mosomal layers in mitosis and the smaller nuclei of daughter cells leading to the problem in mitosis
(Booth et al., 2014). However, although Ki-67 is known to play an important role in cell proliferation,
the mechanism by which Ki-67 regulates cancer progression remains unclear.
As a nuclear protein, Ki-67 interacts with other nuclear proteins (Sueishi et al., 2000;
Takagi et al., 2001). Increasing research focused on the interaction between Ki-67 and other nuclear
proteins has paved the way for the elucidation of the mechanism by which Ki-67 regulates cancer
progression. Nucleolar protein interacting with the forkhead-associated (FHA) domain of pKi-67
(NIFK) is a nucleolar and cytoplasmic protein that interacts with Ki-67 (Takagi et al., 2001; Li et al.,
2004; Byeon et al., 2005). NIFK binds to the FHA domain of Ki-67 by two key regulators of mitosis:
cyclin-dependent kinase 1 (CDK1) and glycogen synthase kinase GSK-3 (Byeon et al., 2005), and
the NIFK sequential phosphorylation at Thr238 and Thr234 is required for the Ki-67 interaction
(Byeon et al., 2005). During mitosis, both NIFK and Ki-67 are recruited to the chromosome periph-
ery, and the localization of NIFK at the peripheral of mitotic chromosome is disrupted in the absence
of Ki-67 (Booth et al., 2014; Van Hooser et al., 2005). This critical role of the NIFK-Ki-67 interaction
in regulating mitosis renders NIFK as a promising target of cancer research. However, to date, stud-
ies focused on the importance of NIFK in cancer are lacking, and no clear evidence has emerged to
elucidate whether and how NIFK regulates cancer progression.
The Wnt/b-catenin signaling pathway is critical during tumorigenesis and metastasis in various
types of cancer (Polakis, 2000; Sinnberg et al., 2010). Stabilization and nuclear import of b-catenin
eLife digest Cancer cells can rapidly divide to form a tumor. Small groups of cells can leave the
tumor to migrate to other sites in the body, and it is these “secondary” tumors that are often
responsible for the death of cancer patients. Many proteins influence how and when cells divide and
migrate. One such protein called Ki67 is only produced when cells are dividing and it is often used in
the clinic as a marker to indicate whether cells have become cancerous. However, it is not clear how
Ki67 regulates the progression of cancer.
Ki67 interacts with another protein called NIFK, and Lin, Su et al. have now investigated the role
of NIFK in cancer. First, publicly available data on the levels of proteins in tumor samples from
cancer patients were analyzed. This revealed that, in several different types of cancer, tumors that
produced more NIFK were more likely to spread to other parts of the body than tumors that
produced smaller amounts of NIFK.
Next, Lin, Su et al carried out experiments using human lung cancer cells. This revealed that cells
that produced larger amounts of NIFK were more likely to migrate, while cells with lower levels of
NIFK divided and migrated less often. Further experiments showed that NIFK increases the activity
of genes that are involved in cell migration. NIFK achieves this by reducing the production of a
protein that inhibits the activity of another protein called b-catenin.
Lin, Su et al.’s findings reveal a new role for NIFK in promoting the development of cancer. A
future challenge is to find out whether chemicals that inhibit NIFK could be used in the treatment of
lung cancer.
DOI: 10.7554/eLife.11288.002
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activates downstream transcriptional targets, MMP7, MYC, TCF4, CCND1 and CD44 which are
related to cell cycle, differentiation and metastasis regulation (Schwartz et al., 2003; Dey et al.,
2013; Cho et al., 2011). b-catenin is constantly synthesized but is normally controlled at restricted
low concentration by proteasome-mediated degradation. Degradation of b-catenin is shown to be
regulated via sequential phosphorylation by casein kinase 1a (CK1a) first, and then by GSK-3, which
facilitates the formation of the destruction complex (Hernandez et al., 2012; Li et al., 2012). CK1
family members including CK1a are constitutively active in cells (Price MA, 2006). Therefore, CK1a
function is determined by its intracellular level. However, the mechanism of CK1a expression regula-
tion in tumors, especially in lung cancer remains obscure.
In this study, we aimed to characterize the role of NIFK, an important Ki-67 binding partner, in
cancer progression. The significant association between NIFK and Ki-67 expression in approximately
20 cancer types based on samples from over 7000 patients in a public database confirmed the
importance of NIFK in cancer. We focused our study on lung cancer due to the strongest prognostic
value of NIFK for lung cancer. Surprisingly, our results revealed NIFK significantly promotes cancer
migration and invasion in vitro and tumor metastasis in vivo in addition to its ability to regulate can-
cer proliferation. Furthermore, we demonstrated that NIFK modulates lung cancer metastasis by reg-
ulating TCF4/b-catenin signaling via the alternation of Casein kinase 1a (CK1a) expression. Our
study indicates that NIFK expression promotes cancer metastasis and proliferation leading to poor
clinical outcomes; thus, NIFK may represent a prognostic indicator and a promising therapeutic tar-
get for lung cancer patients.
Results
NIFK expression is most concurrently elevated with Ki67 in lung cancer
and lung cancer patients displaying high NIFK level exhibit frequent
lymph node and distant metastasis
Due to the well-known characteristics of NIFK as a Ki-67-interacting protein, we first analyzed the
expression level of NIFK and Ki-67 based on a public database. Using The UCSC cancer genomics
browser web resource, 16 cancer types from the TCGA pan-cancer cohort were analyzed. A signifi-
cantly positive correlation between MKI67IP (NIFK) and MKI67 (Ki-67) was observed in almost all can-
cer types (Figure 1A). High MKI67IP expression was observed in lung, colorectal, breast, uterine,
bladder, head and neck, melanoma, cervical, and ovarian cancer. In these high MKI67IP-expressing
cancer types, the most significant positive correlation between MKI67IP and MKI67 expression was
detected in lung cancer (r = 0.488, p<0.001). Based on the heat map, we also observed that the nor-
mal tissue group tended to display low MKI67IP expression. IHC analysis revealed significantly
higher expression of NIFK in the samples from our patient cohort than in the paired normal tissue
for lung and colorectal cancer but not breast cancer (Figure 1B). To identify the cancer types in
which NIFK exerts the most significant impact on cancer progression, we examined the prognostic
value of NIFK for various cancer types using the PrognoScan database. High MKI67IP expression
was associated with poor survival in several cancer types, including lung, breast, and blood cancer
(Figure 1C). By ranking the hazard ratios from the Cox proportional hazards survival model, we
determined that high MKI67IP expression corresponded to the highest hazard ratio in lung cancer
patients (hazard ratio = 4.71, Cox p value = 0.000308). Based on clinicopathological analysis of lung
cancer, the patients displaying high NIFK protein expression exhibited more frequent nodal involve-
ment (p = 0.032) and distant metastasis (p = 0.036), as well as a higher pathological stage (p =
0.059) (Figure 1D). Similar results were observed in a lung cancer cohort from the TCGA database
(Figure 1—figure supplement 1). According to the above results, NIFK displayed the greatest clini-
cal significance for lung cancer and may be associated with lung cancer progression by regulating
tumor metastasis.
NIFK promotes the migration and invasion of lung cancer cells in vitro
Based on the prognostic significance of NIFK and the strong correlation between NIFK and Ki-67
expression in lung cancer, we further investigated the functional role of NIFK in vitro and in vivo. In
12 lung cancer cell lines, the endogenous NIFK levels were normalized to those of the normal lung
cell line Beas2B (Figure 2A, Top), and the relative NIFK levels were statistically analyzed (Figure 2A,
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Bottom). Then, we stably overexpressed NIFK in A549 and PC13 cells, which exhibit low NIFK
expression, via lentiviral infection (Figure 2B). A significant increase in cell migration after NIFK over-
expression was observed in the wound-healing assay (p<0.001 for 4 MOI, Figure 2C). Increased cell
migration and invasion upon NIFK overexpression were confirmed by the transwell assay with short
incubation time (Figure 2—figure supplement 1). In addition, higher endogenous NIFK levels were
Figure 1. NIFK expression is most concurrently elevated with Ki67 in lung cancer and lung cancer patients displaying high NIFK level exhibit frequent
lymph node and distant metastasis. (A) In the TCGA pan-cancer cohort, significantly positive correlations between MKI67IP (NIFK) and MKI67 (Ki-67)
RNA expression were observed in almost all cancer types. Among the cancer types that displayed high MKI67IP expression, lung cancer exhibited the
strongest correlation between MKI67IP and MKI67 expression. Red color in heat map represents genes with high expression. Blue color in heat map
represents gene with low expression. (B) Based on IHC analysis, significant overexpression of NIFK compared with paired normal tissue was observed in
lung cancer (upper) and colorectal cancer (lower left) but not in breast cancer (lower right). (C) Forest plot comparison of the hazard ratio of MKI67IP
(NIFK) overexpression in patients with various cancer types revealed that lung cancer displayed the strongest impact of NIFK RNA expression on
survival. (D) Lung cancer patients displaying NIFK overexpression exhibited more frequent lymph node and distant metastasis and a higher pathological
stage.
DOI: 10.7554/eLife.11288.003
The following figure supplement is available for figure 1:
Figure supplement 1. MKI67IP is overexpressed in tumors and its expression correlates with the pathological TNM stage in lung cancer.
DOI: 10.7554/eLife.11288.004
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Figure 2. NIFK promotes the migration of lung cancer cells in vitro. (A) The endogenous expression levels of NIFK in lung adenocarcinoma (Left),
squamous and large cell lung cancer cell lines (Right). The relative expression levels were normalized to those of normal Beas2B lung cells, and the
average expression levels are presented. (B) The relative NIFK levels in A549 and PC13 cells after overexpression of NIFK via lentiviral infection. (C) The
migratory capacity of NIFK-overexpressing A549 and PC13 cells was assessed using a wound-healing assay. The exposed area was measured after the
indicated incubation period and was normalized to that of the 0-h control. (D) The NIFK knockdown efficiencies in the lentivirus-based shRNA clones
sh5 and sh6, corresponding to H661 and H1299 cells, respectively. NS, non-silenced control. (E) H661 and H1299 cell migration after NIFK knockdown
was evaluated at the indicated time points.
DOI: 10.7554/eLife.11288.005
The following figure supplement is available for figure 2:
Figure supplement 1. The overexpression of NIFK promotes cell migration, invasion in vitro and metastasis in vivo.
DOI: 10.7554/eLife.11288.006
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detected in H661 and H1299 cells, which were derived from metastatic sites in lung cancer patients
(ATCC) and are considered to be invasive (Figure 2A). Therefore, we established stable NIFK-
silenced H661 and H1299 clones using lentivirus-based shRNA-mediated knockdown (Figure 2D).
Cell migration was inhibited after NIFK knockdown, especially in clone sh6 (p<0.01, Figure 2E).
The in vitro results revealed that NIFK could promote cell migration and invasion.
NIFK facilitates cancer cell metastasis in vivo and is associated with
poor survival of lung cancer cohorts
Additionally, in vivo animal model experiments were performed to examine whether NIFK promotes
tumor metastasis. A549 cells overexpressing NIFK were injected into NSG mice via the tail vein
(Figure 3A). Increased lung metastasis was observed in the NIFK-overexpressing group both grossly
and microscopically (p = 0.0127, Figure 3B–C and Figure 3—figure supplement 1). Similarly, signifi-
cantly reduced numbers of metastatic lung nodules were observed in the NIFK-silenced H661 cell-
injected group (p = 0.0054) and in the NIFK-silenced H1299 cell-injected group (p = 0.0169) com-
pared with the corresponding non-silenced (NS) control cell-injected groups (Figure 3D–E). Repre-
sentative images of HE staining and IHC staining for NIFK are presented in Figure 3F. In our patient
cohort, high NIFK IHC expression significantly correlated with poor overall survival in both the Taiwa-
nese (p = 0.018) and Korean (p = 0.041) lung cancer cohorts (Figure 3G–H). These results including
clinical data suggest a regulatory role of NIFK in lung cancer progression, especially in tumor
metastasis.
NIFK promotes cell proliferation via the poor prognosis marker Ki-67
Due to the previously characterized NIFK as a Ki-67-interacting protein, we therefore studied the
regulatory role of NIFK in cell proliferation. NIFK downregulation in H661 and H1299 cells decreased
the cancer proliferation at 96 hr in vitro (Figure 4A). Furthermore, H1299 cell with NIFK silencing dis-
played the reduced tumor weight and volume in vivo p<0.01, Figure 4B–C). The NIFK-regulated cell
proliferation was Ki-67-dependent that Ki-67 silencing decreased cell growth in both A549 and PC13
cells (Figure 4D). In addition, the effect of NIFK Ki-FHA binding, RNA recognition motif (RRM) trun-
cation and T234A/T238A point mutation on cell proliferation was compared with ectopic expression
of wild type (WT) NIFK (Figure 4E–F). Based on Figure 4F, both RRM and Ki-FHA binding domain
were involved in tumor proliferation, but the latter was more significant. In lung cancer cohort, we
observed positive correlation of high NIFK/Ki-67 with poor survival at protein level (Figure 4G, p =
0.004) and significant expression coefficient (Figure 4H, p<0.001). The results potentially indicated
the requirement of Ki-67 in NIFK-increased cell proliferation and the significance of NIFK and Ki-67
in lung cancer progression.
Knowledge-based analysis of the microarray data reveals that NIFK
regulate CK1a and Wnt signaling
The importance of NIFK in clinical patients motivated us to explore the molecular mechanism under-
lying NIFK-mediated lung cancer metastasis. Knocking down Ki-67 expression by shRNA1 in NIFK-
overexpressing PC13 cells and H1299 cells did not impact NIFK-induced cell migration or invasion
(Figure 5A–D). Therefore, we performed microarray analysis of PC13 cells overexpressing NIFK. The
signature of genes displaying a1.5-fold change in expression upon NIFK overexpression was sub-
jected to Ingenuity Pathway Analysis (IPA) and MetaCore database analysis (Supplementary file
1A). Based on the MetaCore enrichment analysis, Wnt signaling, a previously identified pivotal path-
way in regulating cancer metastasis was most strongly affected by NIFK overexpression (Figure 5E–
F). The levels of CK1a and the adenomatous polyposis coli (APC)-AXIN-CK1a-CTNNb-GSK3b com-
plex were decreased following NIFK overexpression, indicating that CK1a is a key molecule in the
NIFK-regulated Wnt signaling pathway (Figure 5G–H, Figure 5—figure supplement 1). Based on
these bioinformatics results, we hypothesized that NIFK overexpression downregulates CK1a,
thereby decreasing the levels of the APC-AXIN-CK1a-CTNNb-GSK3b complex, which in turn
increases intracellular b-catenin protein stability. The increased nuclear fraction of b-catenin was
observed upon NIFK overexpression (Figure 5I) as well as the reduced b-catenin phosphorylation
(Figure 5—figure supplement 2). Furthermore, we determined whether TCF/b-catenin transcrip-
tional activity is affected by the NIFK/CK1a axis. The results of TCF/b-catenin reporter assay
Lin et al. eLife 2016;5:e11288. DOI: 10.7554/eLife.11288 6 of 21
Research article Cell biology
Figure 3. NIFK facilitates cancer cell metastasis in vivo and is associated with poor survival of lung cancer cohorts. (A) The level of NIFK overexpression
following infection of A549 cells with 4 MOI virus. (B) The indicated cells were injected into NSG mice via the tail vein. Surface lung nodules were
statistically quantified. N=5 per group. (C) Representative images of surface lung nodules with HE staining and IHC staining for NIFK are presented for
the RFP- or NIFK-overexpressing cell-injected groups. (D) The NIFK knockdown efficiency in H661 and H1299 cells. (E) The cells were injected via the
tail vein of the mice. Top, representative images of lung metastasis of the indicated H661 and H1299 cells. Bottom, statistical quantification of lung
metastatic nodules in the indicated groups. (F) Top, representative images of lung HE staining. Middle, images of HE staining in the indicated areas.
Bottom, IHC staining for NIFK in the indicated areas. (G) Representative images of IHC staining for NIFK. (H) Kaplan-Meier survival analysis revealed
that high NIFK IHC expression correlates with poor prognosis in lung cancer.
DOI: 10.7554/eLife.11288.007
The following figure supplement is available for figure 3:
Figure supplement 1. Cells overexpressing NIFK or RFP were injected via the tail vein.
DOI: 10.7554/eLife.11288.008
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Figure 4. NIFK promotes cell proliferation via the poor prognosis marker Ki-67. (A) H661 and H1299 cells were seeded at a density 5104 cells/well.
The number of cells was counted at 48 and 96 hr via the Trypan blue exclusion assay. (B) Box plot represented tumor weight of H1299 cell NS clone and
NIFK-silenced clone at 4 weeks after injection. (C) Growth curves of tumor volume in indicated groups. (D) Cell numbers of NIFK overexpressing A549
and PC13 cells upon Ki-67 silence. (E) Overexpression of GFP-tagged wild type (WT), truncated and point mutated NIFK in PC13 cells. Cells were
transiently transfected via liposome and selected. (F) Cell numbers of indicated groups were evaluated at 48 hr after cell seeding at density 5104 cells/
well in 6 wells plate. (G) Kaplan-Meier survival analysis revealed the correlation of NIFK and Ki-67 IHC expression with poor prognosis in lung cancer. (H)
The correlation of NIFK and Ki-67 IHC expression in lung cancer.
DOI: 10.7554/eLife.11288.009
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Figure 5. Knowledge-based analysis of the microarray data reveals that NIFK regulate CK1a and Wnt signaling.
(A) The relative knockdown efficiencies of Ki-67 in (A) PC13 and (C) H1299 cells. Cell migration and invasion were
evaluated via the transwell assay using (B) PC13 and (D) H1299 cells. (E) List of the top 10 signaling pathways
altered by NIFK overexpression. The microarray data of NIFK overexpression in PC13 cells were analyzed using the
MetaCore Maps database. (F) List of the top 10 networks affected by NIFK overexpression. The gene signatures
were processed via the MetaCore Networks database. (G) Representative signature of genes displaying a1.5-fold
Figure 5 continued on next page
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revealed the decreased luciferase activity in the NIFK-silenced cells. Additional knockdown of CK1a
restored TCF/b-catenin transcriptional activity in both NIFK-silenced H661 and H1299 cells (p<0.01,
Figure 5J). In addition, the downstream transcriptional targets of TCF/b-catenin, including TCF4,
CD44, CCND1 and MMP7, were regulated by the NIFK-CK1a axis (Figure 5—figure supplement 3).
The upregulated downstream transcriptional targets were further confirmed by another microarray
analysis of PC13 cells with lentiviral-based stable NIFK overexpression (Figure 5—figure supple-
ment 4 and Supplementary file 1B, labeled in red). These data indicated that NIFK might regulate
TCF/b-catenin-mediated transcriptional events via CK1a.
RUNX1 may act as a transcription factor of CK1a to participate in the
NIFK-induced downregulation of CK1a mRNA expression
Knocking down NIFK expression elicited CK1a upregulation, which decreased the downstream
inhibitory target b-catenin in the H661 and H1299 cell lines (Figure 6A, Left). In addition, NIFK over-
expression using a lentivirus decreased CK1a expression and increased b-catenin level in A549 and
PC13 cells (Figure 6A, Right). A similar result was observed following transient overexpression of
NIFK (Figure 6—figure supplement 1). To investigate the potential mechanism underlying the
NIFK-mediated regulation of CSNK1A1 (CK1a) transcription, we performed a search using the
TFSEARCH website to identify putative transcription factors that may bind to the promoter. Several
potential transcription factors were identified according to the matched consensus binding sequen-
ces of each candidate transcription factor to the CSNK1A1 (Ensembl:ENSG00000113712) promoter
region (Figure 6B). RUNX1 and SRY scored 100 with respect to the matched sequences. The pro-
moter region from -969 to -127 bp was found to be important for transcriptional activation, indicat-
ing the potential involvement of SRY and RUNX1 (Figure 6C). Thus, we determined the involvement
of these transcription factors in regulating the expression level of CK1a. Silencing of RUNX1 and
SRY expression in H1299 cells using shRNA decreased the CK1a expression levels (Figure 6D),
whereas no change in CK1a expression was detected following knockdown of another putative tran-
scription factor, CdxA (Figure 6—figure supplement 2). Furthermore, The ChIP assay was per-
formed on NS H1299 cells and the NIFK-silenced H1299 cell clone sh6 to explore whether the
binding of the predicted transcription factors to the promoter region is regulated by NIFK. As shown
in Figure 6E, increased promoter binding of RUNX1 was observed in the NIFK-silenced H1299 cell
clone sh6 compared with the NS control clone (Top panel). In a complementary experiment, the
overexpression of NIFK in PC13 cells decreased the promoter binding of RUNX1 (Figure 6E, Bottom
panel). However, this regulation was not significantly observed for SRY based on the ChIP experi-
ment (Figure 6E). Thus, we ruled out the involvement of SRY in the NIFK/CK1a axis. To further
determine whether RUNX1 affects CK1 promoter activity, we performed the reporter assay. Our
Figure 5 continued
change in expression due to NIFK overexpression in PC13 cells. The red and green bars represent upregulation
and downregulation, respectively. (H) Knowledge-based IPA analysis of the microarray data focusing on CK1a
(CSNK1A1)-mediated signaling. The red and green circles represent upregulation and downregulation,
respectively. (I) The nuclear levels of b-catenin in cells with NIFK overexpression were showed. Nuclear fractions
were extracted from A549 and PC13 cells. (J) TCF/LEF transcriptional activity alteration in the indicated H661 and
H1299 cells. TOPflash: reporter plasmid with TCF binding sites. FOPflash: reporter plasmid with mutated TCF
binding sites.
DOI: 10.7554/eLife.11288.010
The following figure supplements are available for figure 5:
Figure supplement 1. NIFK down-regulates CK1a, and up-regulates b-catenin level especially in nucleus.
DOI: 10.7554/eLife.11288.011
Figure supplement 2. Phospho-b-catenin levels are decreased after NIFK overexpression.
DOI: 10.7554/eLife.11288.012
Figure supplement 3. NIFK regulates downstream transcriptional targets of TCF4/LEF via CK1a.
DOI: 10.7554/eLife.11288.013
Figure supplement 4. NIFK regulates downstream transcriptional targets of b-catenin.
DOI: 10.7554/eLife.11288.014
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Figure 6. NIFK regulates CK1a expression via the destabilization of transcription factor RUNX1. (A) Left, the levels
of CK1a and b-catenin in H661 and H1299 cells after NIFK knockdown. Right, the levels of the indicated molecules
in A549 and PC13 cells upon NIFK overexpression. (B) Identification of cis-regulatory elements within the
CSNK1A1 (Ensembl:ENSG00000113712) promoter region. The locations of the consensus binding sites relative to
the transcription start site (TSS) are presented below the indicated transcription factors. The scores were
calculated by the TFSEARCH website according to the matched sequences. BRE, B recognition element. Inr,
initiator element. (C) The CK1 promoter region from -969 to -127 bp is important for transcriptional activation. The
relative luciferase activity was measured 48 hr post-transfection with a reporter plasmid containing the CK1
promoter or the indicated deletion mutant. (D) The expression of the indicated molecules after the knockdown of
Figure 6 continued on next page
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results revealed increased CK1 reporter activity after NIFK knockdown in H1299 cells, which was
decreased by RUNX1 knockdown (p<0.001, Left, Figure 6F). In addition, the relative luciferase activ-
ity was dose-dependently decreased by NIFK overexpression in PC13 cells (p<0.001, Right,
Figure 6F). Furthermore, RUNX1 mRNA level was found to be destabilized upon NIFK overexpres-
sion (Figure 6G and Figure 6—figure supplement 3), and the promoter activity was decreased by
NIFK (Figure 6H). Inversely, RUNX1 was increased upon NIFK silencing (Figure 6I). In addition, the
NIFK-mediated RUNX1 repression might be relevant to its FHA and RRM domain (Figure 6—figure
supplement 4). However, the binding of NIFK with RUNX1 mRNA and with RUNX1 protein were not
detected (RNA binding protein IP and protein IP data not shown). Therefore, the mechanism needs
further to be investigated. In the lung cancer cohort, the NIFK and RUNX1 or CK1a RNA levels were
inversely correlated, whereas the RUNX1 and CK1a RNA expression levels were positively correlated
(p<0.001, Figure 6J). These results suggested that RUNX1 is a potential transcriptional factor of
CSNK1A1 (CK1a) that is negatively regulated by NIFK to decrease CK1a expression.
NIFK promotes lung cancer metastasis via CK1a and lung cancer
patients with high NIFK/low CK1a represent poor survival rate
We further investigated whether NIFK-induced tumor metastasis is mediated by the CK1a. CK1a
expression was reduced in H661 and H1299 cells via lentivirus-based shRNA-mediated knockdown
in conjunction with NIFK silencing using sh6 to determine the functional role of CK1a (CK1a sh1-3,
Figure 7A). Knocking down CK1a expression restored cell migration compared with the NIFK knock-
down-only group, although the effects on clones sh1 and sh2 were clearer than those on clone sh3
(Figure 7B, Figure 7—figure supplement 1). These results suggested that the effect of NIFK on cell
migration may be regulated by CK1a. Next, we performed animal experiments to examine whether
CK1a is involved in NIFK-regulated tumor metastasis. The formation of surface lung nodules was sig-
nificantly restored due to CK1a knockdown in the H661 and H1299 sh6 cells (Figure 7C–D, upper
left). This restoration of tumor metastasis was further confirmed via HE staining of the lung tissue
(Lower left, Figure 7C–D). The quantifications for the number of metastatic lung nodules in each
group are presented (Right, Figure 7C–D). These results suggested that NIFK regulates lung cancer
metastasis via CK1a. In support of this hypothesis, we observed that high levels of CK1a correlated
with a favorable prognosis in lung cancer patients (p = 0.051) (Table 1 and Figure 7E). Furthermore,
the combination of NIFK (MKI67IP) and CK1a (CSNK1A1) may represent a superior prognostic
Figure 6 continued
the transcription factors SRY and RUNX1 in the NIFK-silenced H1299 cell clone sh6. (E) ChIP was performed on
H1299 (Top) and PC13 cells (Bottom) using antibodies against RUNX1 and SRY. M, DNA marker. NC, negative
beads control. (F) A CK1 promoter reporter assay was performed on NIFK-silenced H1299 cells (Left) and in NIFK-
overexpressing PC13 cells (Right). The cells were lysed 48 hr after reporter plasmid transfection. The relative
luciferase activity was normalized to the number of cells and was quantified. (G) A549 cells were transiently
transfected with RFP control or NIFK by lipofection. After 48 h, cells were treated with actinomycin D (5 mg/ml) for
indicated time points. Relative RUNX1 mRNA levels were analyzed by RT-PCR. (H) RUNX1 promoter activity was
measured after 48 hr of transfection by liposome. (I) NIFK, CK1a and RUNX1 protein levels were analyzed in H1299
cells upon NIFK silencing. (J) Correlation between the expression levels of the indicated molecules in the lung
cancer cohort. The microarray data were retrieved from the TCGA database
(genomic_TCGA_LUAD_exp_HiSeqV2_percentile_clinical).
DOI: 10.7554/eLife.11288.015
The following figure supplements are available for figure 6:
Figure supplement 1. A549 and PC13 cells were transfected with Flag-tagged NIFK or a vector control for 48 hr.
DOI: 10.7554/eLife.11288.016
Figure supplement 2. RUNX1 and SRY are potential transcription factors of CK1a.
DOI: 10.7554/eLife.11288.017
Figure supplement 3. NIFK overexpression leads to RUNX1 mRNA instability.
DOI: 10.7554/eLife.11288.018
Figure supplement 4. NIFK decreases RUNX1 at RNA level.
DOI: 10.7554/eLife.11288.019
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indicator for lung cancer (p = 0.01) (Figure 7E). Figure 7F represents the model that NIFK promotes
lung cancer progression by (1) downregulating CK1a expression through the destabilization of its
novel transcription factor, RUNX1, to promote lung cancer metastasis as well as (2) increasing the Ki-
67-dependent cell proliferation.
Figure 7. NIFK promotes lung cancer metastasis via CK1a and lung cancer patients with high NIFK/low CK1a represent poor survival rate. (A) The
CK1a knockdown efficiencies of 3 lentivirus-based shRNAs in H661 and H1299 cells. (B) Wound-healing assays were performed on the cells in the
indicated groups. The quantification of the migration of H661 and H1299 cells is presented. (C&D) Animal studies were performed on the indicated
groups. Left, representative images of lung metastasis and lung HE staining of NSG mice injected with (C) H661 cells or (D) H1299 cells. Right, statistical
quantification of the number of metastatic nodules in each group is presented. (E) Kaplan-Meier plot demonstrating the disease-free survival of 226
lung cancer patients displaying varying (upper left) NIFK (MKI67IP) and (upper right) CK1a (CSNK1A1) expression levels. (Lower) Kaplan-Meier plot
demonstrating the disease-free survival of cases separated into high NIFK/low CK1a and low NIFK/high CK1a groups. The data were retrieved from the
microarray analysis of the GSE31210 dataset. (F) The model of NIFK-induced activation of TCF/b-catenin transcriptional activity via the Runx-1-
dependent downregulation of CK1a in metastasis.
DOI: 10.7554/eLife.11288.020
The following figure supplement is available for figure 7:
Figure supplement 1. NIFK promotes cancer cell migration via CK1a.
DOI: 10.7554/eLife.11288.021
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Discussion
In this study, we demonstrate that NIFK promotes cancer progression by regulating cancer metasta-
sis and proliferation. Lung cancer patients displaying high NIFK expression exhibited poor prognosis
and frequent lymph node and distant metastasis. Although Ki-67 has been a research emphasis of
cancer, Ki-67-interacting proteins have not been given the attention that they merit and are gener-
ally considered to regulate cancer proliferation via their physiological roles in mitosis and the cell
cycle (Booth et al., 2014; Byeon et al., 2005; Florian and Mayer, 2011). Hklp2/KIF15, another Ki-
67 interacting protein, plays a critical role in the maintenance of spindle bipolarity during cell division
and was reported to serve as a breast cancer tumor antigen (Florian and Mayer, 2011; Rath and
Kozielski, 2012; Scanlan et al., 2001). NIFK was previously implicated as a c-Myc-responsive gene
in breast cancer (Musgrove et al., 2008). The significant cancer metastasis-promoting characteristics
of NIFK demonstrated by our results provide novel insight into the role of NIFK in cancer. Further-
more, aside from its role as a proliferation marker, Ki-67 has been demonstrated to be associated
with metastasis and lymphovascular invasion in cancer patients (Pollack et al., 2004; Inwald et al.,
2013). However, our results imply that Ki-67 may not affect cancer metastasis via its interaction with
NIFK.
We showed the NIFK-induced cell proliferation is dependent on Ki-FHA binding motif indicating
the requirement of NIFK-Ki-67 interaction in lung cancer proliferation. Ki-67 was reported as a key
factor organizing chromosomal periphery during cell mitosis, and silence of Ki-67 might elicit cell
death (Booth et al., 2014). NIFK interacts with Ki-67 in mitotic phase, and whether the interaction is
critical in nuclear organization remains to be explored. Our previous study characterized the role of
NIFK in U2OS cell proliferation as well as the requirement of its RRM for rRNA maturation
(Pan et al., 2015). However, Ki-67 interacting motif of NIFK also plays a role in regulating cell prolif-
eration especially after long-term incubation as compared with the immediate response of RRM
deletion in U2OS cell (Pan et al., 2015). Both results evidently point on NIFK as a gatekeeper in the
maintenance of well-regulated cell cycle. The discrepancy of RRM efficacy in proliferation among
two studies might potentially due to the difference in cell type-specific mechanism.
CK1a, a component of the b-catenin destruction complex, is characterized as a negative regulator
that blocks Wnt signaling pathway-mediated metastasis (Clevers, 2006). In the canonical Wnt signal-
ing pathway, the level of intracellular b-catenin is modulated by proteasomal degradation mediated
by destruction complex, which is composed of APC, Axin, CK1a, and GSK3b (MacDonald et al.,
2009). Given that b-catenin and APC mutation is less commonly observed in lung cancer than in
other cancer types such as colon cancer, understanding the mechanism by which these Wnt signaling
inhibitors regulate the b-catenin destruction complex is crucial (Stewart, 2014). Many studies have
demonstrated that the downregulation of the members of the b-catenin destruction complex, includ-
ing CK1a, is commonly observed in lung cancer cell lines and cancer tissue and correlates with poor
prognosis or poor clinicopathological characteristics (Yang et al., 2013; Srivastava et al., 2012;
Lee et al., 2013). In our study, we found that NIFK acts as a critical regulator that prevents CK1a-
Table 1. Cox univariate and multivariate regression analysis of CSNK1A1 (CK1a) expression for relapse-free survival in GSE31210 lung
cancer dataset
Univariate Multivariate
Survival Variable HR (95% CI) P HR (95% CI) P
Relapse free
(n=246)
CSNK1A1 (high/low) 2.261 (0.975-5.245) 0.057 1.804 (0.769-4.231) 0.175
Age 1.658 (0.984-2.796) 0.058 1.638 (0.97-2.766) 0.065
Sex (female/male) 1.271 (0.778-2.075) 0.338 0.986 (0.489-1.986) 0.968
Smoking habit (never/ever) 1.333 (0.815-2.178) 0.252 1.19 (0.589-2.402) 0.628
Stage (I/II) 3.163 (1.92-5.21) 0.001 2.912 (1.745-4.862) 0.001
DOI: 10.7554/eLife.11288.022
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mediated b-catenin degradation, which in turn leads to cancer metastasis. Therefore, these results
highlight NIFK as a novel regulator of the Wnt/b-catenin signaling pathway.
In our study, we also observed the sole downregulation of CK1a upon NIFK overexpression,
whereas the expression levels of other components of the destruction complex were not significantly
altered. Recently, a negative feedback loop of Wnt signaling activation was reported via the Huwe-
1-dependent ubiquitylation of Dishevelled (Dvl) (de Groot et al., 2014). Upon Wnt signaling activa-
tion, Dvl recruits Axin and GSK3-b away from the destruction complex, thereby inhibiting b-catenin
destruction complex formation and, subsequently, b-catenin degradation (de Groot et al., 2014;
Stambolic et al., 1996; Behrens et al., 1998). Correspondingly, we detected significant Huwe-1
upregulation based on the microarray data of NIFK overexpression, suggesting the activation of an
alternative negative feedback loop via the decrease in Dvl activity (Supplementary file 1A).
Although this negative feedback might serve to regulate lung cancer progression via GSK-3b, CK1a,
as the downstream rate-determining enzyme that sequentially phosphorylates b-catenin prior to
GSK3b (Hernandez et al., 2012), remains to play a significant role in NIFK regulated b-catenin
degradation.
An additional interesting finding in our data is that higher levels of NIFK were observed in p53
loss-of-function mutation H661 cell lines and in p53-null H1299 cell lines. The repression of CK1a
expression significantly restored the tumor metastatic ability inhibited by NIFK downregulation in
these p53-deficient cell lines. These results implicated the critical role of the NIFK-CK1a-b-catenin
pathway in p53-deficient lung cancer. Previous studies have demonstrated that CK1a plays a role as
a tumor suppressor in p53-inactivated cancer cells (Elyada et al., 2011; Huart et al., 2009;
Chen et al., 2005). The loss of heterozygosity of CK1a results in highly invasive carcinoma in a p53-
deficient mouse model (Elyada et al., 2011). Because p53 inactivation is a major pathogenic event
in lung cancer (Herbst et al., 2008), further research is necessary to determine the role of NIFK-
mediated CK1a expression in p53-deficient lung cancer.
Our study revealed that the molecular mechanism underlying NIFK-mediated CK1a downregula-
tion in lung cancer is RUNX1-dependent at the transcriptional level. RUNX1 was originally recog-
nized to display tumor-suppressive ability due to its role in acute myeloid leukemia tumorigenesis
(Miyoshi et al., 1991; Silva et al., 2003). The loss of RUNX1 from intestinal epithelial cells signifi-
cantly induced tumorigenesis in a conditional knockout mouse model (Fijneman et al., 2012), and
the knockdown of RUNX1 in breast cancer cells resulted in hyperproliferation and abnormal morpho-
genesis (Wang et al., 2011; Janes, 2011). Cancer metastasis due to the inhibitory effect of NIFK on
the binding of RUNX1 to the CK1a promoter region, as demonstrated by our study, represents a
novel tumor progression mechanism that merits further investigation.
In conclusion, NIFK, a Ki-67-interacting protein, is first identified with clinical significance in lung
cancer progression. NIFK enhances the metastatic ability of lung cancer cells via the Runx-1-depen-
dent repression of CK1a expression and activates TCF/b–catenin signaling, thereby promoting
metastasis in lung cancer. In addition, cell proliferation is positively regulated by NIFK via Ki-67.
High NIFK expression correlates with poor prognosis and tumor metastasis in clinical lung cancer
patients, suggesting that NIFK is an independent prognostic indicator and a promising therapeutic
target.
Materials and methods
Patients
Tissue samples of non-small cell lung cancer, breast cancer, and colorectal cancer from patients
were included to further analyze the clinicopathological role of NIFK. For non-small cell lung cancer,
a total of 188 patients from Kaohsiung Medical University Hospital and National Taiwan University
Hospital of Taiwan were included. Another tissue microarray using a Korean cohort of non-small cell
lung cancer patients was purchased from SuperBioChips (SuperBioChips Laboratories, Seoul, Korea).
For breast cancer, we examined samples from 84 patients from Kaohsiung Veterans General Hospi-
tal. For colorectal cancer, 62 patients were enrolled from Taipei Medical University Hospital. All
cases were staged according to the cancer staging manual of the American Joint Committee on
Cancer, and the histological cancer type was classified according to the World Health Organization
classification. The tissues used were obtained with approval from the IRBs of Kaohsiung Medical
Lin et al. eLife 2016;5:e11288. DOI: 10.7554/eLife.11288 15 of 21
Research article Cell biology
University Hospital (KMUH-IRB-20110286), National Taiwan University Hospital, Kaohsiung Veterans
General Hospital (VGHKS12-CT9-057), and Taipei Medical University Hospital (IRB-99049). No
informed consent was required because the data were analyzed anonymously
Cell culture
PC9, PC13 and PC14 cells were developed at the National Cancer Center Hospital in Tokyo, Japan
(Lee et al., 1985). The other nine human lung cancer cell lines were obtained from American Type
Culture Collection (Manassas, VA, USA). Cell lines were purchased by Prof. Michael Hsiao at 2012
and 2013 with certificates of analysis including cell authentication by STR analysis and mycoplasma
contamination test. The H1355, PC9, H358, H928, H520, H157, H661, and H460 cells were main-
tained in RPMI 1640 medium. The PC13, PC14, A549 and H1299 cells were maintained in DMEM.
Each medium was supplemented with 10% fetal bovine serum, penicillin (100 units/ml), and strepto-
mycin (100 mg/ml). The cells were incubated in a humidified atmosphere consisting of 95% air and
5% CO2 at 37˚C.
Wound healing assay
The wound healing assay was assessed using culture inserts (Ibidi, Martinsried, Germany). The culture
inserts were transferred to plates. The cells were seeded at a density of 2  105 cells/well and were
allowed to attach. After incubation, the culture inserts were removed using sterile tweezers and
washed with PBS. The plates were filled with culture medium supplemented with 2% serum to induce
cell migration. The cells were photographed for quantification of closure of the exposed area. The
denuded area closure was calculated by (Denuded distance 0 h   Denuded distance Endpoint) /
Denuded distance 0 h.
Animal study
All animal experiments were conducted in accordance with a protocol approved by the Academia Sin-
ica Institutional Animal Care and Utilization Committee (IACUC, Protocol# 14-03-665). Age-matched
male NSG mice (6 to 8 weeks of age) were used. To evaluate metastasis, 1  106 cells were resus-
pended in 0.1 ml of PBS and injected into the lateral tail vein (n=6). Metastatic lung nodules were
counted and were further confirmed via HE staining using a dissecting microscope.
Lentivirus-based shRNA production and infection
The lentiviral shRNA constructs were purchased from Thermo Scientific (Pittsburgh, PA, USA). Lentivi-
ruses were produced via co-transfection of 293T cells with an shRNA-expressing plasmid, an envelope
plasmid (pMD.G) and a packaging plasmid (pCMV-dR8.91) using calcium phosphate (Invitrogen, Carls-
bad, CA, USA). The 293T cells were incubated for 18 hr, followed by replacement of the culture
medium. The viral supernatants were harvested and titered at 48 and 72 hr post-transfection. The cell
monolayers were infected with the indicated lentivirus in the presence of polybrene and were further
selected using puromycin.
TOP/FOP-Flash assay
The cells were co-transfected with the TOP-Flash (for TCF binding sites) or FOP-Flash (for mutated
TCF binding sites) reporter plasmid (Millipore, Bedford, MA, USA) and pZsGreen (GFP) for 48 hr. The
cells were harvested and lysed using a Promega luciferase assay kit (Madison, WI, USA) according to
the manufacturer’s instructions. The luminescence was measured using a luminometer. The TOP/FOP
luminescence ratio was used as a measure of TCF/b-catenin transcriptional activity.
Preparation of NIFK expression plasmid
NIFK was cloned from Beas2B cDNA using TAKARA DNA polymerase (Mountain View, CA, USA)
according to the manufacture’s instruction. The primer sequences designed were as follows: 5’-
ACCCAAGCTGGCTAGCATGGCGACTTTTTCTGGCCCG-3’ (sense) and 5’- TCAAGATCTAGAATTC
TCACTGATTGCTGCTTCTTCG-3’ (antisense). The PCR products were gel-purified, digested with
NheI/EcoRI, and subcloned into lentiviral expression vector pLAS3W (RNAi Core, Academia Sinica,
Taipei, Taiwan). The sequences were confirmed via DNA sequencing by Sequencing Core Facility, SIC,
Academia Sinica.
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Western blot analysis
The cells were lysed at 4˚C in RIPA buffer containing 50 mM Tris-HCl (pH 7.4), 150 mMNaCl, 1% Triton
X-100, 0.25% sodium deoxycholate, 5 mM EDTA (pH 8.0), and 1 mM EGTA supplemented with prote-
ase and phosphatase inhibitors. After 20 min of lysis on ice, the cell debris was removed via microcen-
trifugation, followed by rapid freezing of the supernatants. The protein concentration was determined
using the Bradford method. In our experiments, equivalent loads of 25–50 g of protein were electro-
phoresed using a SDS-polyacrylamide gel and then electrophoretically transferred from the gel to a
PVDF membrane (Millipore, Bedford, MA, USA). After blocking with 5% non-fat milk, the membrane
was incubated in specific primary antibodies (NIFK: Abcam, ab13880, 1:1000; Ki-67: Dako, Code
M7240, 1:500; CK1a: Abcam, ab88079, 1:1000; non-phospho-b-catenin: Cell Signaling, #8814,
1:1000; phospho-b-catenin (Ser45): Cell Signaling, #9564, 1:1000; RUNX1: Cell Signaling, #4336,
1:1000) overnight at 4˚C and subsequently incubated in a corresponding horseradish peroxidase-con-
jugated secondary antibody for 1 hr. The membranes were visualized using the ECL-Plus detection kit
(PerkinElmer Life Sciences, Boston, MA, USA).
Migration and invasion assay
The in vitro migration and invasion were assessed using Transwell assay (Millipore, Bedford, MA,
USA). For invasion assay, transwell was additional pre-coated with 35 l of 3X diluted matrix matrigel
(Bd Biosciences Pharmingen, San Diego, CA, USA) for 30 min. Cells of 2  105 in serum-free culture
medium were added to the upper chamber of the device, and the lower chamber was filled with 10%
FBS culture medium. After indicated hours of incubation, upper surface of the filter was carefully
removed with a cotton swab. The filter was then fixed, stained and photographed. Cells of migration
and invasion were quantified by counting the cells in three random fields per filter.
Preparation of promoter constructs
The 1.3K bp CSNK1A1 promoter fragment (Ensembl:ENSG00000113712) was cloned from genomic
DNA of H1299 cells. The primer sequences designed were as follows: 5’- CCCCGGTACCCTGAC
TTAAGATGATAGCAT-3’ (sense) and 5’-TTTGCTAGCG CTGGGCCACT TGTTTCTCG-3’ (antisense).
The 1.1K bp RUNX1 promoter was cloned from 293T cells using RUNX1_Promter1_F: 5’-AAAAGG
TACCAAGCCAGTGGGGCCGGAAAA-3’ and RUNX1_Promoter1_R: 5’-TGGGGCTAGCGGTTGTTTA
TGAGGCCCAAA-3’. PCR was performed using TAKARA DNA polymerase (Mountain View, CA, USA)
according to the manufacture’s instruction. The PCR products were gel-purified, digested with KpnI/
NheI, and subcloned into pGL4.20 firefly luciferase vector (Promega, Madison, WI, USA). The sequen-
ces of cloned promoter region were confirmed by DNA sequencing.
Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed according to the manufacture’s instruction (Abcam, Cambridge, MA, USA).
Briefly, Cells were fixed with 1% formaldehyde and quenched by 1.25 M glycine. Cells were then lysed
and immunoprecipitated overnight with antibodies against RUNX1 (Cell Signaling Technology, Dan-
vers, MA, USA) or SRY (Santa Cruz, CA, USA). After immunoprecipitation, protein A beads were added
for 1 hr to capture the immune complexes. The beads were washed, and the cross-link was further
reversed. DNA was purified and analyzed by RT-PCR analysis. The primer sequences were as follows:
RUNX1: 5’- ACTGAGGTTTTCAACAAGACCA -3’ (sense) and 5’-ATCCCCCTGCCATCCTATGT-3’
(antisense) with product size of 223 bp. SRY: 5’-ACCATGGAGTTTTCTTTCGTGA-3’ (sense) and 5’-
TGGTCTTGTTGAAAACCTCAGT-3’ (antisense) with product size of 214 bp.
Semi-quantitative RT-PCR and real-time PCR amplification analysis
Total cellular RNA was extracted by TRIzol reagent (Invitrogen, Carlsbad, CA, USA) in accordance with
the manufacturer’s instructions. One microgram of total RNA was reverse-transcribed using Advan-
tage RT for PCR Kit (Clontech, Mountain View, CA, USA) at 42˚C for 1 hr as described in the manufac-
turer’s protocol. PCR conditions for rat leptin were 94˚C for 5 min and 37 cycles at 94˚C for 30 s, 56 C
for 30 s and 72˚C for 60 s, followed by a final extension step at 72˚C for 5 min by Bio-Rad icycle (Bio-
Rad). Primer sequences were as follows: human CCND1: 5’-GACCTTCGTTGCCCTCTGT-3’ (sense)
and 5’-TGAGGCGGTAGTAGGACAGG-3’ (antisense) with product size of 180 bp; human MMP7: 5’-
TGGGAACAGGCTCAGGACTAT-3’ (sense) and 5’-CGTCCAGCGTTCATCCTCAT-3’ (antisense) with
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product size of 504 bp; human TCF4: 5’-CCGATGACGAGGGTGATGAG-3’ (sense) and 5’-CCGAG-
GACACCTTCTCTTCC-3’ (antisense) with product size of 399 bp; human CD44: 5’-GGATCCACCC-
CAACTCCATC-3’ (sense) and 5’-AGGTCCTGCTTTCCTTCGTG-3’ (antisense) with product size of 702
bp; human MKI67IP (NIFK): 5’-AGGTGGCGCAGGTTCGCAAG-3’ (sense) and 5’-TGGTGTGGGGCCC
TGGCTATC-3’ (antisense) with product size of 632 bp; human GAPDH: 5’-GTCCACTGGCGTC
TTCACCACC-3’ (sense) and 5’-AGGCATTGCTGATGATCTTGAGGC-3’ (antisense) with product size
of 161 bp. For each combination of primers, the kinetics of PCR amplification was studied. The number
of cycles corresponding to plateau was determined and PCR was performed at exponential range.
PCR products were then electrophoresed through a 1% agarose gel and visualized by ethidium bro-
mide staining in UV irradiation. The mRNA levels were also determined by real-time PCR with ABI Ste-
pOnePlus real-time PCR system according to the manufacturer’s instructions. GAPDH was used as
endogenous control. PCR reaction mixture contained the SYBR PCR master mix, 50 ng cDNA, and pri-
mers. Relative gene expression level that the amount of target were normalized to endogenous con-
trol gene was calculated using the comparative Ct method formula E-44Ct. The primer sequences
were as follows:
RUNX1_F:5’-AGCCCCAACTTCCTCTGCTC-3’
RUNX1_R:5’-TCATCATTGCCAGCCATCAC-3’.
Statistical analysis
Estimates of the survival rates were calculated using the Kaplan-Meier method and were compared
using the log-rank test. The association between clinicopathological categorical variables and NIFK
expression was analyzed using the chi-squared test. Student’s t-test was used for other statistical anal-
yses. All data are presented as the mean ± S.D. The p values at the following levels were considered to
be significant: *p<0.05, **p<0.01, and ***p<0.001. All data was represented after at least three
repeated experiments with a similar pattern.
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